Moleculin announces strong physician intent to prescribe Annamycin in R/R AML; likelihood-to-prescribe score 6/7

Moleculin Biotech, Inc.

Oncologists reported average likelihood-to-prescribe Annamycin of 6 out of 7, citing deep remissions and reduced cardiotoxicity.
Physicians highlighted Annamycin's biomarker-agnostic applicability and potential to bridge patients to bone marrow transplant.
Payers viewed Annamycin as a potentially valuable addition for R/R AML, driven by efficacy and safety profile.
Key differentiators include MRD-negative responses and reduced cardiotoxicity, especially important for pediatric and repeat dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.